Streetbeat News

Products Services

KRYS

The U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code for Krystal Biotech's Vyjuvek, a treatment for Dystrophic Epidermolysis Bullosa, which will be effective from January 1, 2024. This J-code facilitates billing and reimbursement processes for Vyjuvek, potentially improving its market accessibility and adoption.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:12 pm

BIIB

DNA

Ginkgo Bioworks has successfully completed a collaboration with Biogen, aimed at enhancing the productivity of Biogen's gene therapy manufacturing platform. This collaboration could potentially lead to more efficient production processes for gene therapies.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:11 pm

EVO

Shares of Evotec SE (EVO) are down in premarket trading after the announcement that CEO Werner Lanthaler is stepping down for personal reasons. Despite this, Evotec confirmed its 2023 revenue guidance of €750-790 million. Additionally, Evotec has entered into an AI-powered multi-target collaboration with Owkin, focusing on oncology, immunology, and inflammation. This partnership will leverage Owkin's AI for target discovery and Evotec's R&D platform, with Evotec receiving R&D funding, potential milestone payments, and royalties from Owkin.

Portfolio Pulse from Nabaparna Bhattacharya

January 04, 2024 | 12:11 pm

MRNS

Marinus Pharmaceuticals forecasts U.S. net product revenue of $32M-$34M for Ztalmy in FY24. This projection is a significant financial update for investors, indicating the company's expectations for the commercial performance of Ztalmy.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:09 pm

V

Visa has launched the Visa Web3 Loyalty Engagement Solution, a new service designed to enhance customer engagement and loyalty in digital and virtual worlds. This service includes features such as gamified giveaways, augmented reality treasure hunts, and innovative methods for earning and redeeming loyalty points.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:08 pm

MRNS

Marinus Pharmaceuticals forecasts FY23 revenues for Ztalmy (Ganaxolone) to be between $19.5M-$19.7M, with Q4 revenues estimated at $6.5M-$6.7M.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:08 pm

ONCY

Oncolytics Biotech announced plans to initiate its first Phase 3 study for Pelareorep in pancreatic cancer within the year. Additionally, the company will offer guidance on the registration path for metastatic breast cancer in the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:08 pm

ENTA

Enanta Pharmaceuticals announced its plans for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference, including an update on its pipeline. The company is expanding into immunology with a new oral KIT inhibitor program for CSU, aiming for development candidate selection in 2024. Enanta also expects topline data from a Phase 2 study of Zelicapavir (EDP-938) for RSV treatment in 3Q 2024, and challenge study data for EDP-323, another RSV treatment, in the same quarter.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:07 pm

ACET

Adicet Bio, Inc. (NASDAQ:ACET) aims to advance its pipeline of allogeneic gamma delta T cell therapies in 2024, focusing on oncology and autoimmune diseases. The FDA cleared an IND for ADI-001 in lupus nephritis, with a Phase 1 trial expected in Q2 2024. In hematologic malignancies, ADI-001 showed promising results in MCL patients, and a clinical update is anticipated in the second half of 2024. The company also plans to file an IND for ADI-270, targeting renal cell carcinoma, in Q2 2024. Adicet Bio's cash runway is projected to last into the second half of 2025.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:04 pm

AAPL

13-year-old Willis Gibson from Oklahoma achieved a historic Tetris score of '999999' on the original Nintendo version, surpassing the game's 'kill screen' and setting a record previously thought to be only possible by AI. The New York Times reported this achievement, which adds to Tetris's legacy as the top-selling video game. Apple Inc. partnered with PlayStudios in March 2023 to offer a free trial of Apple TV+ to Tetris players, highlighting the game's ongoing popularity.

Portfolio Pulse from Benzinga Neuro

January 04, 2024 | 12:03 pm